Antibody raised against Rho GTPase activating protein 26 (ARHGAP26), a negative regulator of G proteins RhoA and Cdc42. ARHGAP26 is a molecular switch regulating tumour cells.
Catalogue number crb2005668 Antibody Anti-ARHGAP26 antibody Antigen Peptide KLH conjugated synthetic peptide crb1200877e Protein ID Q9UNA1 ARHGAP26 Aliases Rho GTPase-activating protein 26, GTPase regulator associated with focal adhesion kinase, Oligophrenin-1-like protein, Rho-type GTPase-activating protein 26 Host Species Rabbit Antibody Type Polyclonal Concentration 2.0mg/ml Glycine (R2G), 1.0mg/ml Glycine (R1G) Target ARHGAP26 Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References
Katoh, M. and Katoh, M. (2004). Characterization of human ARHGAP10 gene in silico. International Journal of Oncology, 25(4), pp.1201–1207.
Zhang, L., et al. (2021). The role of GTPase-activating protein ARHGAP26 in human cancers. Molecular and Cellular Biochemistry, 477(1), pp.319–326.
Rho GTPase Activating Protein 26 (ARHGAP26) is a rho family negative regulator, used to convert G proteins RhoA and Cdc42 into their inactive forms. It can exist in multiple forms, with ARHGAP10 being a paralog gene of particular significance. As a type of GTPase-activating protein, ARHGAP26 has the capacity to enhance hydrolysis of GTPases, converting them from an active to an inactive form, therefore inhibiting signal transduction.
This type of protein plays an important role in regulation of the behaviour of cancer cells, this occurs through ARHGAP26 being a GTPase-activating protein, meaning it can inhibit Rho-GTPases by promoting their hydrolytic ability. ARHGAP26 can also have an affect on tumorigenesis and tumour progression, by forming abnormal fusion genes, tumour development and progression can be both slowed down or sped up by ARHGAP. Understanding the molecular mechanisms of ARHGAP26 could help unearth its potential clinical value in cancer treatments.